Switch to:
Also traded in: Germany, UK, USA
» Details

Insider Trades

Latest Guru Trades with HCM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412 
Compare:OTCPK:MAYNF, OTCPK:HAWPF, NAS:AERI, AMEX:TXMD, NAS:RTRX, NAS:ASMB, NAS:RMTI, NAS:NBRV, NAS:ZGNX, OTCPK:AGYTF, NAS:OASM, NAS:ALIM, OTCPK:BIOYF, AMEX:NNVC, AMEX:AXN, NAS:PRPH, NAS:NVGN, NAS:IMNP, OTCPK:SUWN, OTCPK:CHEXF » details
Traded in other countries:H7T.Germany, HCM.UK, HNCMF.USA,
Hutchison China Meditech Ltd and its subsidiaries is engaged in researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products. It also market and sell organic and natural consumer products in Asia.

Hutchison China Meditech Ltd is a biopharmaceutical company incorporated in the Cayman Islands on December 18, 2000. The Company along with its subsidiaries is engaged in researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products. The Company's clinical-stage drug candidates includes Savolitinib a potential inhibitor of the mesenchymal epithelial transition factor, or c-Met, receptor tyrosine kinase, an enzyme which has been shown to function abnormally in many types of solid tumors; Fruquintinib a selective and potent oral inhibitor of the vascular endothelial growth factor receptor, or VEGFR; Sulfatinib an oral drug candidate that selectively inhibits the tyrosine kinase activity associated with VEGFR and fibroblast growth factor receptor 1, or FGFR1, a receptor for a protein which also plays a role in tumor growth; HMPL-523 a potential oral inhibitor targeting the spleen tyrosine kinase, or Syk, a key protein involved in B-cell signaling; Epidermal growth factor receptor, or EGFR, inhibitors have revolutionized the treatment of non-small cell lung cancer with EGFR activating mutations; and theliatinib is a potent and selective oral EGFR inhibitor engineered to have greater binding affinity to wild-type EGFR proteins. The Company faces competition from different sources, including pharmaceutical, specialty pharmaceutical and biotechnology companies.

Ratios

vs
industry
vs
history
P/B 10.35
HCM's P/B is ranked lower than
89% of the 827 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.02 vs. HCM: 10.35 )
Ranked among companies with meaningful P/B only.
HCM' s P/B Range Over the Past 10 Years
Min: 8.65  Med: 18.09 Max: 41.93
Current: 10.35
8.65
41.93
P/S 12.34
HCM's P/S is ranked lower than
82% of the 766 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.06 vs. HCM: 12.34 )
Ranked among companies with meaningful P/S only.
HCM' s P/S Range Over the Past 10 Years
Min: 9.26  Med: 13.27 Max: 46.6
Current: 12.34
9.26
46.6
Current Ratio 2.18
HCM's Current Ratio is ranked lower than
56% of the 726 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.49 vs. HCM: 2.18 )
Ranked among companies with meaningful Current Ratio only.
HCM' s Current Ratio Range Over the Past 10 Years
Min: 0.85  Med: 1.27 Max: 2.18
Current: 2.18
0.85
2.18
Quick Ratio 2.08
HCM's Quick Ratio is ranked higher than
55% of the 725 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.84 vs. HCM: 2.08 )
Ranked among companies with meaningful Quick Ratio only.
HCM' s Quick Ratio Range Over the Past 10 Years
Min: 0.84  Med: 1.17 Max: 2.08
Current: 2.08
0.84
2.08
Days Inventory 22.05
HCM's Days Inventory is ranked higher than
93% of the 687 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.19 vs. HCM: 22.05 )
Ranked among companies with meaningful Days Inventory only.
HCM' s Days Inventory Range Over the Past 10 Years
Min: 17.86  Med: 136.94 Max: 448.99
Current: 22.05
17.86
448.99
Days Sales Outstanding 70.02
HCM's Days Sales Outstanding is ranked higher than
54% of the 628 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.32 vs. HCM: 70.02 )
Ranked among companies with meaningful Days Sales Outstanding only.
HCM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 26.75  Med: 81.01 Max: 155.16
Current: 70.02
26.75
155.16
Days Payable 72.49
HCM's Days Payable is ranked higher than
51% of the 574 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.12 vs. HCM: 72.49 )
Ranked among companies with meaningful Days Payable only.
HCM' s Days Payable Range Over the Past 10 Years
Min: 53.45  Med: 68.42 Max: 91.09
Current: 72.49
53.45
91.09

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.80
HCM's 3-Year Average Share Buyback Ratio is ranked higher than
59% of the 436 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.40 vs. HCM: -2.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
HCM' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -11.8  Med: -0.4 Max: 0
Current: -2.8
-11.8
0

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 66.60
HCM's Price/Net Current Asset Value is ranked lower than
95% of the 542 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. HCM: 66.60 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
HCM' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 7.69  Med: 33.63 Max: 67
Current: 66.6
7.69
67
Price/Tangible Book 10.57
HCM's Price/Tangible Book is ranked lower than
85% of the 747 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.65 vs. HCM: 10.57 )
Ranked among companies with meaningful Price/Tangible Book only.
HCM' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.12  Med: 9.08 Max: 33.29
Current: 10.57
3.12
33.29
Price/Projected FCF 49.33
HCM's Price/Projected FCF is ranked lower than
99.99% of the 320 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.66 vs. HCM: 49.33 )
Ranked among companies with meaningful Price/Projected FCF only.
HCM' s Price/Projected FCF Range Over the Past 10 Years
Min: 0  Med: 32.67 Max: 49.63
Current: 49.33
0
49.63
Price/Median PS Value 0.93
HCM's Price/Median PS Value is ranked higher than
68% of the 703 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.13 vs. HCM: 0.93 )
Ranked among companies with meaningful Price/Median PS Value only.
HCM' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.12  Med: 0.92 Max: 2.77
Current: 0.93
0.12
2.77
Earnings Yield (Greenblatt) (%) -1.40
HCM's Earnings Yield (Greenblatt) (%) is ranked lower than
72% of the 835 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. HCM: -1.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
HCM' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -2.02  Med: 0.2 Max: 0.2
Current: -1.4
-2.02
0.2

More Statistics

Revenue (TTM) (Mil) $197.4
EPS (TTM) $ -0.22
Short Percentage of Float0.03%
52-Week Range $9.80 - 16.06
Shares Outstanding (Mil)120.57

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 202 220 256 357
EPS ($) 0.01 -0.29 -0.36 -0.21
EPS w/o NRI ($) 0.01 -0.29 -0.36 -0.21
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for HCM

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Chi-Med Initiates a Phase II Study of Savolitinib in Pulmonary Sarcomatoid Carcinoma Feb 20 2017
Chi-Med Initiates a Phase II Study of Savolitinib in Pulmonary Sarcomatoid Carcinoma Feb 20 2017
Hutchison China Meditech Limited: Start of Phase II Savolitinib PSC trial in China Feb 20 2017
Chi-Med and AstraZeneca Present Savolitinib Papillary Renal Cell Carcinoma Phase II Results at 2017... Feb 14 2017
Chi-Med and AstraZeneca Present Savolitinib Papillary Renal Cell Carcinoma Phase II Results at 2017... Feb 14 2017
Chi-Med and AstraZeneca Present Savolitinib Papillary Renal Cell Carcinoma Phase II Results at 2017... Feb 14 2017
Chi-Med Initiates First-In-Human Clinical Trial of Novel FGFR Inhibitor HMPL-453 in Australia Feb 14 2017
Chi-Med Initiates First-In-Human Clinical Trial of Novel FGFR Inhibitor HMPL-453 in Australia Feb 14 2017
Hutchison China Meditech Limited: Initiates Phase I of Novel FGFR Inhibitor HMPL-453 Feb 14 2017
Hutchison China Meditech Limited: Savolitinib PRCC Results Presentation at ASCO GU Feb 14 2017
Chi-Med to Announce 2016 Final Results Feb 06 2017
Chi-Med appoints Industry Veteran Karen Ferrante to Board of Directors Feb 01 2017
Chi-Med appoints Industry Veteran Karen Ferrante to Board of Directors Feb 01 2017
Hutchison China Meditech Limited: Change of Directors Feb 01 2017
Hutchison China Meditech Limited: Change of Directors Jan 16 2017
Chi-Med appoints Industry Veteran Paul Carter to Board of Directors Jan 16 2017
Chi-Med appoints Industry Veteran Paul Carter to Board of Directors Jan 16 2017
Chi-Med Presents Phase I/II Clinical Data for Selective VEGFR Inhibitor Fruquintinib at the 2017... Jan 16 2017
Chi-Med Presents Phase I/II Clinical Data for Selective VEGFR Inhibitor Fruquintinib at the 2017... Jan 16 2017
Chi-Med Initiates a Phase II Study of Sulfatinib in Second-line Biliary Tract Cancer in China Jan 16 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK